



TSX Venture Exchange: CCG  
FOR IMMEDIATE RELEASE

## CardioComm Solutions Inc. Announces “Gypsy Swap” Transaction

**VICTORIA, B.C., February 14, 2006** – CardioComm Solutions Inc. (TSX-V:CCG) (the "Company", "CardioComm"), today announced that a shareholder who is an officer and director of the Company, has sold 2,600,000 common shares of CardioComm at a price of \$0.05 per share as a “gypsy swap” transaction, through a brokered private placement.

The total net proceeds of the sale of the 2,600,000 common shares of the Company’s stock realized by the seller, sold as a “gypsy swap,” will be reinvested in the company by purchasing 2,600,000 common shares of CardioComm at \$0.05 per share under a private placement. The company will pay any commissions associated with the private placement of the common shares.

### **About CardioComm Solutions Inc:**

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company’s products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMST™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors  
of CardioComm Solutions Inc.:

“Stephen Martin”  
Stephen R. Martin, President & CEO

***For investor information, please  
contact:***

Derek Sutherland  
[IR@CardioComm.com](mailto:IR@CardioComm.com)

**Call 1-416-832-0442**

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release.